It’s harvest time for the most active life sciences hedge fund firm in the private markets.
RA Capital Management is awaiting the initial public offerings of no fewer than five companies in which it previously made investments.
This week alone one of the companies set terms for its IPO, while two others filed initial plans for their offerings.
The
